iRadimed Corporation (NASDAQ:IRMD - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $56.56 and traded as high as $62.07. iRadimed shares last traded at $59.02, with a volume of 57,917 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded iRadimed from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, May 6th.
Check Out Our Latest Stock Report on iRadimed
iRadimed Stock Down 0.1%
The company's 50-day moving average is $56.82 and its two-hundred day moving average is $55.62. The company has a market cap of $760.40 million, a P/E ratio of 38.57 and a beta of 0.91.
iRadimed Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, May 30th. Shareholders of record on Tuesday, May 20th were paid a $0.17 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $0.68 annualized dividend and a dividend yield of 1.14%. iRadimed's payout ratio is presently 43.87%.
Institutional Investors Weigh In On iRadimed
Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in iRadimed by 94.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,108 shares of the medical equipment provider's stock worth $5,506,000 after purchasing an additional 48,534 shares during the period. US Bancorp DE lifted its stake in shares of iRadimed by 476.6% during the 4th quarter. US Bancorp DE now owns 617 shares of the medical equipment provider's stock valued at $34,000 after buying an additional 510 shares in the last quarter. Proficio Capital Partners LLC bought a new position in iRadimed in the 4th quarter worth approximately $926,000. Raymond James Financial Inc. bought a new position in iRadimed in the 4th quarter worth approximately $2,319,000. Finally, Avantax Advisory Services Inc. purchased a new position in iRadimed in the 4th quarter valued at approximately $217,000. Hedge funds and other institutional investors own 92.34% of the company's stock.
About iRadimed
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Further Reading
Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
